Hypoglycemia (low blood glucose) can be very dangerous and is one of the most frightening situations for people with diabetes – particularly during the night when an estimated 57% of people with type 1 diabetes experience a low at least once.[i] Not to mention it impacts their quality of life and takes time out of their day. A person with type 1 diabetes experiences an average of two low blood glucose events a week that they are aware of[ii], but how many more go unnoticed?
What can we do to help people with type 1 diabetes achieve better glucose control?
This is where SmartGuard technology plays a critical role – the only technology on the market proven to reduce the risk of lows*. SmartGuard technology includes Suspend on Low in the new MiniMed 630G system, Threshold Suspend in the MiniMed 530G system, and predictive low glucose management (PLGM) in the MiniMed 640G system (not approved in the US).
How SmartGuard Technology Works
The Suspend on Low feature in the MiniMed 630G system and Threshold Suspend in the MiniMed 530G system automatically suspends insulin delivery for up to two hours when sensor glucose reaches a predetermined low, and if the person does not respond to the alarm.
Watch this video to see how the technology works.
Why It Matters
Addressing one of the biggest challenges of diabetes, SmartGuard has shown to reduce nighttime low glucose events[iii] per week by 30 percent, and severity/duration of those events by 37.5 percent without increasing A1C (a measure of average blood sugar levels over three months).[iv],[v] Real-world data from our CareLink Personal software validates these results.
The reduction in hypoglycemia demonstrates the importance and power of automating insulin delivery, particularly overnight. This means people with diabetes can have a greater peace of mind and sleep better without having to frequently monitor or worry about their blood glucose overnight. For caregivers and loved ones, automated systems can help reduce some of the worry associated with caring for someone with type 1 diabetes. For healthcare systems, this means saving thousands of dollars per year, per patient, through the reduction of costs associated with emergency room visits, accidents, and hospital admissions due to hypoglycemia.
With SmartGuard technology, we are delivering advanced systems that take action against lows so people with diabetes can live more freely, and delivering on our commitment to improving outcomes for everyone touched by diabetes.
Important Safety Information
MiniMed systems featuring SmartGuard technology are intended for the delivery of insulin and continuous glucose monitoring for the management of diabetes mellitus by persons 16 years of age or older who require insulin. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick is required prior to making adjustments to diabetes therapy.
WARNING: The SmartGuard feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the feature, it is important to read the User Guide and discuss proper use with your healthcare provider.
[i] Raju B, Arbelaez AM, Breckenridge SM, Cryer PE. Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments. J Clin Endocrinol Metab.2006;91(6):2087-209.
[ii] Cryer P. The Barrier of Hypoglycemia in Diabetes. Diabetes. 2008;57(12):3169-317.
[iii] < 65 mg/dL, measured in sensor glucose values.
[iv] Based upon limited sample size and duration of ASPIRE In-Home study.
[v] Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369(3):224–232. Study focused on nocturnal events and conclusions reached subject to limited sample size and duration.